Core Viewpoint - Zhenmai Bio has successfully completed a C+ round financing of 280 million yuan, aiming to enhance its commercialization ecosystem and global expansion strategy, thereby accelerating domestic substitution and technological breakthroughs abroad [1][3]. Financing and Strategic Goals - The financing round was led by multiple investors including Shengxiang Bio, Jinyu Medical, and others, which will provide sufficient momentum for market consolidation, capacity expansion, and compliance layout [1]. - The funds will support Zhenmai Bio's strategic goals of commercial ecosystem construction and global expansion [1]. Product Development and Achievements - Zhenmai Bio has launched two flagship products: the SURFSeq 5000, which has the highest global throughput of 2.2 Tb/run, and the SURFSeq Q, which boasts a daily output of 9 Tb, both receiving high recognition from users [2]. - The company has received regulatory approval for two significant medical devices, marking a milestone in domestic high-throughput sequencing technology [2]. Market Expansion and Partnerships - Zhenmai Bio's global business has expanded to over 50 countries and regions, with nearly 500 substantial partnerships, including top research institutions and clinical medical organizations [3]. - The company aims to strengthen its industry advantages and accelerate its position as a global leader in gene sequencing and life omics [3]. Leadership and Investor Insights - The chairman of Zhenmai Bio expressed gratitude for the support from shareholders, emphasizing the strategic resonance between capital, innovation, and industry chains [4]. - Investors highlighted Zhenmai Bio's strong capabilities in sequencing technology and its potential for international breakthroughs, indicating a commitment to deepening collaboration in precision medical technology [5][6].

Core Viewpoint - The report outlines the continuous supervision and assessment conducted by CITIC Securities on BGI Genomics, emphasizing the company's compliance with regulations and the absence of significant issues during the review period [1][3]. Group 1: Continuous Supervision Overview - The sponsor established a continuous supervision work system and a corresponding work plan, clarifying the requirements for on-site inspections [2] - A sponsorship agreement was signed between the sponsor and the company, detailing the rights and obligations during the supervision period, which has been filed with the Shanghai Stock Exchange [2] - The sponsor conducted daily communications and on-site visits, including a site inspection on May 19, 2025 [2] - The supervision included reviewing corporate governance documents, financial management systems, internal control reports, and conducting interviews with senior management [2] Group 2: Issues and Rectification - During the supervision period, no significant issues were identified by the sponsor or the representatives [3]. Group 3: Major Risk Items - The company faces risks of significant performance decline or losses due to high R&D investments and market expansion costs, particularly if international relations worsen or macroeconomic conditions deteriorate [4] - The rapid technological updates in the life sciences sector pose risks related to product development and market acceptance [5] - Risks of core talent loss and technology leakage are significant, impacting R&D capabilities and competitive advantages [6] - Ongoing patent and trademark litigation, particularly with competitors like Illumina, may restrict market expansion and sales performance in affected regions [7] - The company faces intense market competition, especially from established players in the gene sequencing market, which may hinder market share growth [8] Group 4: Financial Performance - In 2024, the company achieved a total revenue of CNY 2,956.89 million, with gene sequencing instruments contributing CNY 2,347.88 million, reflecting a 2.47% year-on-year growth [19] - R&D expenditure as a percentage of revenue decreased by 4.34 percentage points due to efficiency optimization measures [19][29] Group 5: Core Competitiveness - The company has developed a comprehensive product line in gene sequencing, leveraging its proprietary DNBSEQ technology, which enhances sequencing accuracy and efficiency [20][21] - The company has established a strong collaborative ecosystem with various research institutions and industry partners, enhancing its technological capabilities and market reach [24][26] - The management team comprises industry leaders with extensive experience, contributing to the company's innovative capacity and strategic direction [27][28]

AI大潮袭来，唯有学习方能不被淘汰。 全新升级版 的 AI学习资料包 免费下载：《 AI资料包 升级版新增厦大湖南大学等》 特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我 们的推送。 近 日 ， 中 国 科 研 团 队 在 中 国 空 间 站 天 宫 空 间 站 首 次 发 现 并 鉴 定 了 一 个 微 生 物 新 物 种 ， 命 名 为"天宫尼尔菌"。该研究用上我国自主研发的华大智造DNBSEQ-T7测序平台，通过多学科 手段确认新物种。华大智造DNBSEQ-T7测序仪超强，适用于多个领域。这项研究是中国空间 站居留舱微生物监测任务的一部分，样本采集于2023年5月。该菌株有独特特性，研究团队发 现其在多个方面存在差异和突变。总体表明发现于中国空间站的菌株是尼尔菌属中的新物种。 领取方式：关注本号，后台回复"324"无门槛免费领取。 | 版 权 ： 本 文 部 分 素 材 源 自 网 络 ， 版 权 归 原 作 者 所 有 ， 观 点 代 表 作 者 本 人 ， 不 代 表 本 号 立 场 微 信 阅 读 顺 序 改 版 了 ~ 请 帮 小 编 ...

3.2亿年前，当脊椎动物离开水域来到陆地生活时，它们面对的是全新的挑战：如何适应陆地环 境，如何在陆地上找到食物、躲避危险、寻找伴侣。此后进一步演化出的鸟类更是需要适应长时间飞行 迁徙的特殊生活方式。 原标题：新研究揭秘3.2亿年动物大脑进化路径 当人们提到高智商动物时，通常会想到猴子、猩猩等灵长类，或宠物狗、海豚。但鸽子或麻雀等鸟 类，其实也展现出了媲美灵长类的工具使用和社会认知能力。 这听起来或许有点不可思议，但最新科学研究显示，鸟类、哺乳类甚至龟类的大脑在过去3.2亿年 里，经历了一场精彩的演化历程，走出了截然不同但又殊途同归的智慧发展之路。 5月13日，华大生命科学研究院联合中国科学院深圳先进技术研究院、郑州大学生命科学学院、中 国科学院脑科学与智能技术卓越创新中心等机构，共同揭开了跨越3.2亿年的大脑神经元演化之谜。相 关研究论文发表于国际期刊《发育细胞》。 构建跨物种单细胞图谱 形成基因双轨演化机制 鸟类的小脑占全脑的比例较高，细胞类型的复杂程度也相对较高，此前有推测认为这可能与它们适 应飞行等因素相关。 该研究首次在鸟类小脑中鉴定出SVIL+浦肯野细胞亚型，其基因表达谱显著区别于哺乳类的 ALD ...

Financial Data and Key Metrics Changes - The meeting confirmed that a preliminary count of shares indicated a quorum was present, with 158,260,315 shares entitled to vote [4][5] - All proposals presented at the meeting received sufficient votes for approval, including the election of directors and the ratification of Ernst and Young as the independent registered public accounting firm [11] Business Line Data and Key Metrics Changes - No specific business line data or key metrics were discussed in the provided content Market Data and Key Metrics Changes - No specific market data or key metrics were discussed in the provided content Company Strategy and Development Direction and Industry Competition - The company emphasized the importance of forward-looking statements and the potential for actual results to differ from expectations, indicating a focus on strategic planning and risk management [12][13] Management's Comments on Operating Environment and Future Outlook - Management did not provide specific comments on the operating environment or future outlook in the provided content Other Important Information - The meeting included a director resignation provision that allows the board to determine whether to accept or reject the resignation of an incoming director who fails to be reelected, applicable only in uncontested elections [15][17] Q&A Session Summary Question: Does the director resignation provision undermine shareholder voting rights? - Management clarified that the provision is only applicable in uncontested elections and allows the board to consider the totality of circumstances to determine what is in the best interest of shareholders [15][17][18]

Core Viewpoint - The forced liquidation of shares held by the controlling shareholder, Gao Yang, due to a default in a stock pledge repurchase agreement, raises concerns about the financial stability of Berry Genomics and its declining stock price [1][2][5] Group 1: Shareholder Actions and Impacts - Gao Yang, the founder and chairman of Berry Genomics, has had 3,535,214 shares (1% of total shares) ordered for forced liquidation due to a default on a stock pledge with Guosen Securities [1] - All shares held by Gao Yang (9.05% of total shares) are currently under judicial freeze, indicating significant financial distress [3] - The forced execution of shares is part of a broader trend where both Gao Yang and his associate, Hou Ying, have seen their shares subjected to judicial auction due to ongoing financial difficulties [4] Group 2: Financial Performance - Berry Genomics has experienced a continuous decline in revenue and has reported losses for four consecutive years, totaling approximately 9.85 billion yuan [5] - The company's revenue figures from 2021 to 2024 are approximately 14.22 billion yuan, 13.68 billion yuan, 11.51 billion yuan, and 10.78 billion yuan, respectively, with net profits turning negative starting in 2021 [5] - The decline in performance is attributed to market demand changes and increased competition, leading to significant asset impairment provisions [5] Group 3: Stock Performance - The stock price of Berry Genomics has plummeted from a peak of 98 yuan per share in July 2020 to below 10 yuan per share in 2023, reflecting a severe loss of investor confidence [2] - As of May 19, the stock closed at 13.40 yuan per share, down 5.57% [5]

Core Insights - A new microbial species named "Niallia tiangongensis" has been discovered in the Chinese space station, marking a significant advancement in understanding microbial diversity in space [1][2][3] Group 1: Discovery and Significance - The discovery of Niallia tiangongensis expands knowledge of microbial diversity in extreme space environments, showcasing China's capabilities in space exploration [1][2] - The research was published in the International Journal of Systematic and Evolutionary Microbiology, highlighting its scientific importance [2] Group 2: Research Methodology - The research utilized the DNBSEQ-T7 sequencing platform developed by BGI Genomics, which is capable of generating at least 7Tb of data in 24 hours, demonstrating advanced technological capabilities [1][2] - Samples were collected by astronauts during the Shenzhou 15 mission in May 2023, using sterile wipes to gather microbial samples from various surfaces within the space station [3] Group 3: Microbial Characteristics - Niallia tiangongensis is a Gram-positive, aerobic, spore-forming rod with a genome size of 5,166,230 base pairs and a G+C content of 35.6 mol% [3][4] - The species exhibits unique traits, including the ability to hydrolyze gelatin, indicating its adaptability to nutrient-limited environments [4] Group 4: Genetic Analysis - Genomic analysis revealed significant differences between Niallia tiangongensis and its closest terrestrial relative, Niallia circulans, with only 83.3% genomic similarity, below the species definition threshold of 95% [3][4] - Key mutations in proteins associated with oxidative stress response and radiation damage repair were identified, enhancing its survival capabilities in space [4]

深圳华大智造科技股份有限公司 会议资料 深圳华大智造科技股份有限公司 为保障深圳华大智造科技股份有限公司（以下简称"公司"）全体股东的合 法权益，维护股东大会的正常秩序，保证股东大会的议事效率，确保本次股东大 会如期、顺利召开，根据《中华人民共和国公司法》（以下简称《公司法》）、 《深圳华大智造科技股份有限公司章程》（以下简称《公司章程》）、《深圳华 大智造科技股份有限公司股东大会议事规则》及中国证券监督管理委员会、上海 证券交易所的有关规定，特制定本须知。 一、为确认出席大会的股东或其代理人或其他出席者的出席资格，会议工作 人员将对出席会议者的身份进行必要的核对工作，请被核对者给予配合。 二、为保证本次大会的严肃性和正常秩序，切实维护股东的合法权益，请出 席大会的股东或其代理人或其他出席者务必准时到达会场签到确认参会资格，在 会议主持人宣布现场出席会议的股东和代理人人数及所持有的表决权数量之前， 会议登记应当终止，在此之后进场的股东或股东代理人无权参与现场投票表决。 三、会议按照会议通知上所列顺序审议、表决议案。 四、股东及股东代理人参加股东大会依法享有发言权、质询权、表决权等权 利。股东及股东代理人参加股 ...

Core Insights - The presence of tertiary lymphoid organs (PTLOs) in carotid atherosclerotic plaques is closely related to whether patients exhibit symptoms such as stroke, serving as an independent risk factor for symptomatic carotid stenosis [1][2] - The research provides new perspectives on the immune mechanisms of atherosclerosis and identifies potential therapeutic targets for precise interventions [1][3] Group 1: Research Findings - The study utilized single-cell RNA sequencing and spatial omics technology (Stereo-seq) to construct a high-resolution single-cell spatial map of human carotid atherosclerotic plaques [2] - PTLOs were identified in human arterial plaques, characterized by significant spatial aggregation of lymphocytes, lack of typical germinal center structures, and active B cell immune responses [2] - The presence of effector B cells in plaques is linked to the formation of "ectopic germinal center reactions," indicating clonal selection and the potential generation of specific antibodies against plaque antigens [2] Group 2: Clinical Implications - The findings suggest a molecular basis for the interaction between B cells in plaques and those in surrounding vascular adipose tissue, supporting the existence of a "vascular adipose tissue-plaque immune axis" [2] - The study highlights the potential for future clinical diagnostics and interventions in atherosclerosis, particularly through the role of IgG antibodies secreted by effector B cells in activating macrophage functions [2][3]

Market Performance - The market rebounded last week, with the China Securities Xinhua National Brand Index rising by 0.94% to 1666.03 points [1] - The Shanghai Composite Index increased by 0.76%, the Shenzhen Component Index by 0.52%, the ChiNext Index by 1.38%, and the CSI 300 Index by 1.12% [1] Strong Stock Performances - Notable strong performers in the brand index included BGI Genomics, which rose by 17.27%, and Yiling Pharmaceutical, which increased by 9.81% [1] - Other significant gainers included Stone Technology and Marubi Biological, which rose by 7.18% and 6.79%, respectively [1] Year-to-Date Stock Gains - Since the beginning of 2025, Marubi Biological has surged by 60.82%, leading the gains, followed by Shanghai Jahwa with a 46.72% increase and BGI Genomics with a 34.45% rise [2] - Other stocks with notable increases include Anji Technology, Xintai, and Weir Shares, each rising over 20% [2] Market Outlook - Institutions expect the market to refocus on domestic economic fundamentals, with a positive policy response anticipated [2][3] - The current market is viewed as being in a high cost-performance range, with significant policy support expected to stabilize the economy and market [2] Economic Data Focus - Attention is drawn to upcoming economic data, particularly export performance and the sustainability of the export supply chain recovery [3] - The prevailing market conditions are supported by policy measures and liquidity easing, which are expected to bolster the stability of the domestic economy and capital markets [3]